Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous?

Updated Mar 7, 2025 | 01:00 AM IST

SummaryTwin-to-twin transfusion syndrome (TTTS) is a rare pregnancy complication in identical twins sharing a placenta, causing uneven blood flow, which can lead to severe health risks or fatal outcomes if untreated.
Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous

Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

  • 90% of the cases of untreated TTTS lead to loss of one or both twins.
  • Despite treatment, only a 70% survival rate for both twins is assured.
  • Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
  • Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

End of Article

Are Sea Squirts The Future Of Skin Cancer Treatment? New Study Says They Can Kill Melanoma Cells

Updated Jul 1, 2026 | 02:00 AM IST

SummaryA recent study by a Florida-based university found promising results after examining the possibility of using sea squirts to develop a new treatment for melanoma.
Are Sea Squirts The Future Of Skin Cancer Treatment? New Study Says They Can Kill Melanoma Cells

Credit: AI-generated image

Researchers at a Florida-based university claim that a tiny marine animal found in Antarctica can help scientists develop a new treatment for melanoma, one of the deadliest forms of skin cancer. These marine animals are ascidians, invertebrates known as sea squirts. Belonging to the group of tunicates, they mostly thrive in icy water.

Sea Squirts May Help Treat Melanoma

Certain species of marine animals have proven to be useful in the treatment of various types of cancer. The latest ones are ascidians or sea squirts.

Researchers from the University of South Florida (USF) claim that sea squirts, small tube-shaped marine animals that produce protective chemicals, can help fight an aggressive form of skin cancer called melanoma.

Scientists say that these sea squirts have a bacterium that makes a toxic compound. In the early stages of the study, it was found that this compound is capable of killing melanoma cells without harming healthy cells.

Also read: Frequent Headaches: When To See A Doctor And Warning Signs To Watch For

The Study Addresses A Significant Challenge In Cancer Treatment

One of the biggest challenges in cancer treatment is finding drugs that destroy cancer cells while leaving healthy cells unharmed. With this study, scientists say this compound produced by the bacteria inside Antarctic sea squirts can do exactly that, marking a significant milestone in cancer research.

In experiments conducted on mice, it was seen that the compound killed melanoma cells without causing serious harm to the rodents, making it a promising candidate for future drug development.

Even though it shows immense promise, the research is still in its early stages. Before the compound can be tested in people, scientists need to confirm that it is safe and effective in larger animal studies. Clinical trials on humans may still take a while.

Also read: How Reconstructive Plastic Surgery Transforms Lives After Trauma And Cancer

There is also a challenge of harvesting large numbers of sea squirts from Antarctica, as it would damage the fragile ecosystem. To avoid that, researchers are now working on creating the compound in the laboratory instead.

Despite encouraging results, it remains an experimental approach, and several years of research and clinical testing will be needed before it can become a trusted and proven therapy for melanoma.

Marine Animals’ Contribution In Cancer Treatment

Ecteinascidia turbinata, a colonial marine invertebrate, commonly called the golden sea squirt, has contributed to the development of Trabectedin, a chemotherapy drug, used to treat soft tissue sarcoma and ovarian cancer.

One of the significant cancer breakthroughs was due to sea sponges. They led to the development of Cytarabine, a chemotherapy medication that has been significant in the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, and certain lymphomas for decades.

Sea cucumbers contain natural substances that can slow the growth and spread of cancer cells. Although research is still in its early stages, the results have been promising.

Researchers also found a powerful anti-cancer compound called dolastatin in sea hares. It inspired targeted cancer drugs that deliver treatment directly to cancer cells while reducing harm to healthy cells.

End of Article

US Medicare Set To Cover GLP-1 Drugs For Weight Loss: All You Should Know About Eligibility, Costs

Updated Jun 30, 2026 | 07:00 PM IST

SummaryThe new 18-month Medicare GLP-1 Bridge Program, which will run till the end of 2027, aims to make the high-cost GLP-1 weight-loss medications more accessible to eligible beneficiaries.
US Medicare Set To Cover GLP-1 Drugs For Weight Loss: All You Should Know About Eligibility, Costs

Credit: iStock

For the first time, starting July 1, people in the US will be able to access GLP-1 drugs for weight loss through a new pilot program offered by the federal health insurance program Medicare.

Until now, Medicare covered GLP-1 medications such as Ozempic only for certain conditions like diabetes, but not for weight loss.

The new 18-month Medicare GLP-1 Bridge Program, which will run till the end of 2027, aims to make these high-cost weight-loss medications more accessible to eligible beneficiaries.

According to a KFF analysis of 2023 Part D enrollment data, an estimated 3.8 million Medicare beneficiaries could qualify for the program.

More than 70 per cent of adults in the United States are considered to have obesity or screen as overweight. Studies have proven that GLP-1s are an effective tool in weight reduction, as well as improving other markers of good health, such as blood pressure, lipid profiles, and blood sugar levels.

What Drugs Will Be Covered?

Eligible beneficiaries will be able to access the following GLP-1 weight-loss medications:

  • Novo Nordisk's Wegovy injections and tablets
  • Eli Lilly's Foundayo tablets
  • Eli Lilly's Zepbound KwikPen

The medications will be covered only when prescribed for weight management and when beneficiaries meet the program's medical eligibility criteria.

Who Will Be Eligible?

The program is available only to certain members of Medicare Part D prescription drug plans who want to lose excess weight and maintain weight loss.

Although the program operates outside standard Medicare Part D coverage, beneficiaries can participate only if they are enrolled in:

  • An eligible stand-alone Medicare Part D prescription drug plan under Original Medicare, or
  • An eligible Medicare Advantage plan that includes prescription drug coverage.

People enrolled in certain less common Medicare plans, including the Program of All-inclusive Care for the Elderly (PACE), may also qualify if they also have a stand-alone Part D plan, Washington Post reported.

According to the Centers for Medicare & Medicaid Services (CMS), most of Medicare's approximately 57 million Part D enrollees are in eligible plans.

However, coverage is not automatic. Providers and pharmacists will identify eligible patients, submit the required forms and obtain prior authorization before treatment can begin. Claims, prior authorization requests and pharmacy payments will be handled by Humana, while Part D plans will not be involved in the process.

How Much Will It Cost?

Eligible beneficiaries will pay a $50 monthly copay for the covered medications.

However, because the program operates outside Medicare Part D coverage:

  • The $50 copay will not count toward a beneficiary's Part D deductible.
  • It also will not count toward the 2026 Part D annual out-of-pocket spending cap of $2,100.
  • The copay is not eligible for the Medicare Prescription Payment Plan, which allows beneficiaries to spread prescription drug costs throughout the year.

What Happens After 2027?

The pilot program is temporary and is scheduled to end in December 2027, unless it is extended.

"It's certainly good news for Medicare beneficiaries who have been essentially shut out of the market for GLP-1s for weight loss if they wanted to use insurance coverage. However, it is a temporary program. It is not a permanent change in Medicare coverage," said Juliette Cubanski, Vice President and Director of Medicare Policy at KFF.

If the program is not extended, beneficiaries who rely on the medications may have to pay higher out-of-pocket prices or discontinue treatment beginning in January 2028, which experts said could lead to weight regain based on current GLP-1 therapies, the Post reported.

End of Article

New Vitamin B12 Therapy That Crosses Blood-Brain Barrier Shows Promise In Fighting Deadly Brain Cancer: Study

Updated Jun 30, 2026 | 11:03 PM IST

SummaryScientists have discovered that a new vitamin B-12 compound may help in combating glioblastoma by overcoming challenges like breaking the blood-brain barrier and treatment resistance.
New Vitamin B12 Therapy Shows Promise Against Aggressive Brain Cancer, Says Study

Credit: AI-generated image

A recent study has found that a modified form of vitamin B12 therapy may prove to be a new and promising way to treat glioblastoma, one of the most aggressive forms of brain cancer.

With limited treatment options, patients are usually treated with surgery, radiation therapy, and chemotherapy. Usually, the chance of survival is not bright after diagnosis.

New Vitamin B-12 Compound Shows Promise In Glioblastoma Treatment

Published in the journal Oncoscience, the research study is based on nitrosylcobalamin (NO-Cbl), a vitamin B12-based compound that contains and slowly releases nitric oxide.

The main purpose of the study was to find out whether the vitamin B-12 compound could cross the blood-brain barrier, a protective layer that prevents many medicines from reaching the brain and directly targeting glioblastoma tumors.

The blood-brain barrier is one of the biggest challenges in treating glioblastoma, as it protects the brain from harmful substances, blocking many cancer drugs from reaching tumor tissue.

Also read: Ebola Outbreak Spreads To Fourth Province In DR Congo As Cases Rise To 1,274

About The Study

The researchers examined how NO-Cbl affected different types of cancer cells, particularly how it moved through the body of rats with glioblastoma. The results showed that NO-Cbl had an anti-cancer effect on several types of tumors.

Most importantly, the compound was able to cross the blood-brain barrier and accumulate inside glioblastoma tumors in animal studies.

Researchers also found that the compound remained active in tumor tissue for at least 24 hours, delivering nitric oxide directly to cancer cells without affecting normal tissues.

They also tested NO-Cbl in combination with two existing glioblastoma treatments: temozolomide, the standard chemotherapy drug for the disease, and TRAIL, an experimental cancer therapy.

In laboratory-grown glioblastoma cells, the combinations alleviated cancer cell growth much more effectively than any of the treatments used on their own.

Also read: Cholera Outbreak In Sudan: 117 Dead, 838 Suspected Cases, Says WHO

About Glioblastoma

A glioblastoma is a fast-growing glioma, a type of tumor that stems from glial cells, which protect nerve cells in the brain and spinal cord.

Glioblastoma can occur at any age but is more commonly found in older adults. The average age at diagnosis is 64.

Public figures among those afflicted include former President Joe Biden's son, Beau Biden, who succumbed to this cancer in 2015. John McCain also passed away in 2018 due to glioblastoma.

According to the MD Anderson Cancer Center, around 12,000 glioblastoma cases are diagnosed in the United States every year. All glioblastomas are grade IV brain tumors, meaning they contain the most abnormal looking cells and are the most aggressive.

About 13,000 Americans are diagnosed with glioblastoma each year, accounting for almost half of all cancerous brain tumors, according to the Cleveland Clinic. More than 10,000 people in the U.S. will succumb to the disease every year, the National Brain Tumor Society reports.

In the light of limited treatment options for glioblastoma, this study is a ray of hope as it shows promise in slowing down the growth of cancer cells by overcoming challenges like treatment resistance.

End of Article